Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with parkinson's disease

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 582-590

  Little, J P ^a   Villanueva, E B ^a   Klegeris, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

9 tetrahydrocannabinol (THC); Alzheimer's disease; Fever; Marijuana; Microglia; Mitochondrial dysfunction; Oxidative stress; Thermoregulation

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; ENDOCANNABINOID; HU 201; HU 303; MITOCHONDRIAL ENZYME; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; BIOGENESIS; BRAIN MITOCHONDRION; DEGENERATIVE DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; FEVER; HUMAN; INFLAMMATION; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; SIGNAL TRANSDUCTION; THERMOREGULATION;

ANIMALS; ANTIOXIDANTS; CANNABINOIDS; HUMANS; INFLAMMATION; MICROGLIA; PARKINSON DISEASE; PSYCHOTROPIC DRUGS;

EID: 79959920826     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711795906905     Document Type: Article

References (104)

1. Alves, G.; Forsaa, E. B.; Pedersen, K. F.; Dreetz Gjerstad, M.; Larsen, J. P. Epidemiology of Parkinson's disease. J. Neurol., 2008, 255 Suppl. 5, 18-32.
2. Huse, D. M.; Schulman, K.; Orsini, L.; Castelli-Haley, J.; Kennedy, S.; Lenhart, G. Burden of illness in Parkinson's disease. Mov. Disord., 2005, 20(11), 1449-1454.
3. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39(6), 889-909.
4. Hunot, S.; Hirsch, E. C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol., 2003, 53 Suppl. 3, S49-S58; discussion S58-S60.
5. Qian, L.; Flood, P. M.; Hong, J. S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. Neural Transm., 2010, 117(8), 971-979.
6. Dawson, T. M.; Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302(5646), 819-822.
7. Wood-Kaczmar, A.; Gandhi, S.; Wood, N. W. Understanding the molecular causes of Parkinson's disease. Trends Mol. Med., 2006, 12(11), 521-528.
8. Di Filippo, M.; Chiasserini, D.; Tozzi, A.; Picconi, B.; Calabresi, P. Mitochondria and the link between neuroinflammation and neurodegeneration. J. Alzheimers Dis., 2010, 20 Suppl. 2, S369-S379.
9. Stella, N. Endocannabinoid signaling in microglial cells. Neuropharmacology, 2009, 56 Suppl. 1, 244-253.
10. Stella, N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia, 2010, 58(9), 1017-1030.
11. Fernandez-Ruiz, J.; Garcia, C.; Sagredo, O.; Gomez-Ruiz, M.; de Lago, E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin. Ther. Targets, 2010, 14(4), 387-404.
12. Di Marzo, V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat. Neurosci., 2011, 14(1), 9-15.
13. Campbell, V. A. Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology, 2001, 40(5), 702-709.
14. Movsesyan, V. A.; Stoica, B. A.; Yakovlev, A. G.; Knoblach, S. M.; Lea, P. M.T.; Cernak, I.; Vink, R.; Faden, A. I. Anandamideinduced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ., 2004, 11(10), 1121-1132.
15. Downer, E.; Boland, B.; Fogarty, M.; Campbell, V. Delta 9-tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. Neuroreport, 2001, 12(18), 3973-3978.
16. Tedesco, L.; Valerio, A.; Dossena, M.; Cardile, A.; Ragni, M.; Pagano, C.; Pagotto, U.; Carruba, M. O.; Vettor, R.; Nisoli, E. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes, 2010, 59(11), 2826-2836.
17. Klegeris, A.; Bissonnette, C. J.; McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol., 2003, 139(4), 775-786.
18. Esposito, G.; Scuderi, C.; Savani, C.; Steardo, L., Jr.; De Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V.; Steardo, L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol., 2007, 151(8), 1272-1279.
19. Garcia-Arencibia, M.; Gonzalez, S.; de Lago, E.; Ramos, J. A.; Mechoulam, R.; Fernandez-Ruiz, J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptorindependent properties. Brain. Res., 2007, 1134(1), 162-170.
20. Campillo, N. E.; Paez, J. A. Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. Mini Rev. Med. Chem., 2009, 9(5), 539-559.
21. Garcia-Arencibia, M.; Garcia, C.; Fernandez-Ruiz, J. Cannabinoids and Parkinson's disease. CNS Neurol. Disord. Drug Targets, 2009, 8(6), 432-439.
22. Bisogno, T.; Di Marzo, V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. Drug Targets 2010, 9(5), 564-573.
23. Sagredo, O.; Garcia-Arencibia, M.; de Lago, E.; Finetti, S.; Decio, A.; Fernandez-Ruiz, J. Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol., 2007, 36(1), 82-91.
24. Lastres-Becker, I.; Cebeira, M.; de Ceballos, M. L.; Zeng, B. Y.; Jenner, P.; Ramos, J. A.; Fernandez-Ruiz, J. J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 2001, 14(11), 1827-1832.
25. Pisani, A.; Fezza, F.; Galati, S.; Battista, N.; Napolitano, S.; Finazzi-Agro, A.; Bernardi, G.; Brusa, L.; Pierantozzi, M.; Stanzione, P.; Maccarrone, M. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 2005, 57(5), 777-779.
26. Fernandez-Ruiz, J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156(7), 1029-1040.
27. Hampson, A. J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(14), 8268-8273.
28. Marsicano, G.; Moosmann, B.; Hermann, H.; Lutz, B.; Behl, C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem., 2002, 80(3), 448-456.
29. Croxford, J. L.; Miller, S. D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J. Clin. Invest., 2003, 111(8), 1231-1240.
30. Centonze, D.; Rossi, S.; Finazzi-Agro, A.; Bernardi, G.; Maccarrone, M. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int. Rev. Neurobiol., 2007, 82, 171-186.
31. Ullrich, O.; Merker, K.; Timm, J.; Tauber, S. Immune control by endocannabinoids -new mechanisms of neuroprotection? J. Neuroimmunol., 2007, 184(1-2), 127-135.
32. Wolf, S. A.; Tauber, S.; Ullrich, O. CNS immune surveillance and neuroinflammation: endocannabinoids keep control. Curr. Pharm. Des., 2008, 14(23), 2266-2278.
33. Gowran, A.; Noonan, J.; Campbell, V. A. The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration. CNS Neurosci. Ther., (in press).
34. Whitton, P. S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol., 2007, 150(8), 963-976.3
35. McGeer, P. L.; McGeer, E. G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord., 2004, 10 Suppl. 1, S3-S7.
36. Zhang, W.; Wang, T.; Pei, Z.; Miller, D. S.; Wu, X.; Block, M. L.; Wilson, B.; Zhou, Y.; Hong, J. S.; Zhang, J. Aggregated alphasynuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J., 2005, 19(6), 533-542.
37. Klegeris, A.; Giasson, B. I.; Zhang, H.; Maguire, J.; Pelech, S.; McGeer, P. L. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J., 2006, 20(12), 2000-2008.
38. Klegeris, A.; Pelech, S.; Giasson, B. I.; Maguire, J.; Zhang, H.; McGeer, E. G.; McGeer, P. L. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging., 2008, 29(5), 739-752.
39. Hanrott, K.; Gudmunsen, L.; O'Neill, M. J.; Wonnacott, S. 6-Hydroxydopamine-induced Apoptosis Is Mediated via Extracellular Auto-oxidation and Caspase 3-dependent Activation of Protein Kinase C. J. Biol.Chem., 2006, 281(9), 5373-5382.
40. Moriguchi, S.; Mizoguchi, Y.; Tomimatsu, Y.; Hayashi, Y.; Kadowaki, T.; Kagamiishi, Y.; Katsube, N.; Yamamoto, K.; Inoue, K.; Watanabe, S.; Nabekura, J.; Nakanishi, H. Potentiation of NMDA receptor-mediated synaptic responses by microglia. Brain Res. Mol. Brain Res., 2003, 119(2), 160-169.
41. Rawls, S. M.; Tallarida, R. J.; Gray, A. M.; Geller, E. B.; Adler, M. W. L-NAME (N omega-nitro-L-arginine methyl ester), a nitricoxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6 Hpyrrolo[ 3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J. Pharmacol. Exp. Ther., 2004, 308(2), 780-786.
42. Parpura, V.; Haydon, P. G. Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(15), 8629-8634.
43. Ciesielski-Treska, J.; Ulrich, G.; Chasserot-Golaz, S.; Zwiller, J.; Revel, M. O.; Aunis, D.; Bader, M. F. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J. Biol. Chem., 2001, 276(16), 13113-13120.
44. Flavin, M. P.; Zhao, G.; Ho, L. T. Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia, 2000, 29(4), 347-354.
45. Gan, L.; Ye, S.; Chu, A.; Anton, K.; Yi, S.; Vincent, V. A.; von Schack, D.; Chin, D.; Murray, J.; Lohr, S.; Patthy, L.; Gonzalez-Zulueta, M.; Nikolich, K.; Urfer, R. Identification of cathepsin B as a mediator of neuronal death induced by Abeta-activated microglial cells using a functional genomics approach. J. Biol. Chem., 2004, 279(7), 5565-5572.
46. Kingham, P. J.; Pocock, J. M. Microglial secreted cathepsin B induces neuronal apoptosis. J. Neurochem., 2001, 76(5), 1475-1484.
47. Harris, J. E.; Nuttall, R. K.; Elkington, P. T.; Green, J. A.; Horncastle, D. E.; Graeber, M. B.; Edwards, D. R.; Friedland, J. S. Monocyte-astrocyte networks regulate matrix metalloproteinase gene expression and secretion in central nervous system tuberculosis in vitro and in vivo. J. Immunol., 2007, 178(2), 1199-1207.
48. Klegeris, A.; McGeer, P. L. Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity. Glia, 2005, 51(1), 56-64.
49. Na, S. J.; DiLella, A. G.; Lis, E. V.; Jones, K.; Levine, D. M.; Stone, D. J.; Hess, J. F. Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease. Neurochem. Res., 2010, 35(5), 761-772.
50. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J. A.; Mechoulam, R.; Fernandez-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis., 2005, 19(1-2), 96-107.
51. Ternianov, A.; Perez-Ortiz, J. M.; Solesio, M. E.; Garcia-Gutierrez, M. S.; Ortega-Alvaro, A.; Navarrete, F.; Leiva, C.; Galindo, M. F.; Manzanares, J. Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol. Aging, (in press).
52. Wenger, T.; Moldrich, G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66(2-3), 301-307.
53. Clark, W. G. Changes in body temperature after administration of antipyretics, LSD, delta 9-THC and related agents: II. Neurosci. Biobehav. Rev., 1987, 11(1), 35-96.
54. Liu, R. K.; Walford, R. L. The effect of lowered body temperature on lifespan and immune and non-immune processes. Gerontologia, 1972, 18(5-6), 363-388.
55. Fraga, D.; Zanoni, C. I.; Rae, G. A.; Parada, C. A.; Souza, G. E. Endogenous cannabinoids induce fever through the activation of CB1 receptors. Br. J. Pharmacol., 2009, 157(8), 1494-1501.
56. Benamar, K.; Yondorf, M.; Meissler, J. J.; Geller, E. B.; Tallarida, R. J.; Eisenstein, T. K.; Adler, M. W. A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. J. Pharmacol. Exp. Ther., 2007, 320(3), 1127-1133.
57. Cabral, G. A.; Dove Pettit, D. A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol., 1998, 83(1-2), 116-123.
58. Berdyshev, E. V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids., 2000, 108(1-2), 169-190.
59. Klein, T. W.; Newton, C.; Friedman, H. Cannabinoid receptors and immunity. Immunol. Today, 1998, 19(8), 373-381.
60. Roche, M.; Diamond, M.; Kelly, J. P.; Finn, D. P. In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J. Neuroimmunol., 2006, 181(1-2), 57-67.
61. Blatteis, C. M.; Li, S.; Li, Z.; Feleder, C.; Perlik, V. Cytokines, PGE2 and endotoxic fever: a re-assessment. Prostaglandins Other Lipid Mediat., 2005, 76(1-4), 1-18.
62. Archer, R. A. The cannabinoids: therapeutic potentials. Annu. Rep. Med. Chem. 1974, 9, 253-259.
63. Leker, R. R.; Gai, N.; Mechoulam, R.; Ovadia, H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke, 2003, 34(8), 2000-2006.
64. Hayakawa, K.; Mishima, K.; Abe, K.; Hasebe, N.; Takamatsu, F.; Yasuda, H.; Ikeda, T.; Inui, K.; Egashira, N.; Iwasaki, K.; Fujiwara, M. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport, 2004, 15(15), 2381-2385.
65. Krieger, D. W.; Yenari, M. A. Therapeutic hypothermia for acute ischemic stroke: what do laboratory studies teach us? Stroke, 2004, 35(6), 1482-1489.
66. van der Worp, H. B.; Macleod, M. R.; Kollmar, R. Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J. Cereb. Blood. Flow Metab., 2010, 30(6), 1079-1093.
67. Liu, L.; Yenari, M. A. Therapeutic hypothermia: neuroprotective mechanisms. Front. Biosci., 2007, 12, 816-825.
68. Christian, E.; Zada, G.; Sung, G.; Giannotta, S. L. A review of selective hypothermia in the management of traumatic brain injury. Neurosurg. Focus, 2008, 25(4), E9.
69. Tansey, M. G.; McCoy, M. K.; Frank-Cannon, T. C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol., 2007, 208(1), 1-25.
70. Bahniwal, M.; Villanueva, E. B.; Klegeris, A. Moderate increase in temperature may exacerbate neuroinflammatory processes in the brain: Human cell culture studies. J. Neuroimmunol., (in press).
71. Klegeris, A.; Schulzer, M.; Harper, D. G.; McGeer, P. L. Increase in core body temperature of Alzheimer's disease patients as a possible indicator of chronic neuroinflammation: a meta-analysis. Gerontology, 2007, 53(1), 7-11.
72. Salerian, A. J.; Saleri, N. G. Cooler biologically compatible core body temperatures may prolong longevity and combat neurodegenerative disorders. Med. Hypotheses, 2006, 66(3), 636-642.
73. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53 Suppl. 3, S26-S36; discussion S36-S38.
74. Beal, M. F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci., 2003, 991, 120-131.
75. Navarro, A.; Boveris, A. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front. Aging Neurosci., (in press).
76. Devi, L.; Raghavendran, V.; Prabhu, B. M.; Avadhani, N. G.; Anandatheerthavarada, H. K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem., 2008, 283(14), 9089-9100.
77. Sherer, T. B.; Betarbet, R.; Testa, C. M.; Seo, B. B.; Richardson, J. R.; Kim, J. H.; Miller, G. W.; Yagi, T.; Matsuno-Yagi, A.; Greenamyre, J. T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci., 2003, 23(34), 10756-10764.
78. Shimoke, K.; Kudo, M.; Ikeuchi, T. MPTP-induced reactive oxygen species promote cell death through a gradual activation of caspase-3 without expression of GRP78/Bip as a preventive measure against ER stress in PC12 cells. Life Sci., 2003, 73(5), 581-593.
79. Wu, D. C.; Teismann, P.; Tieu, K.; Vila, M.; Jackson-Lewis, V.; Ischiropoulos, H.; Przedborski, S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(10), 6145-6150.
80. Gao, H. M.; Liu, B.; Hong, J. S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci., 2003, 23(15), 6181-6187.
81. Good, P. F.; Hsu, A.; Werner, P.; Perl, D. P.; Olanow, C. W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol., 1998, 57(4), 338-342.
82. Tsang, A. H.; Lee, Y. I.; Ko, H. S.; Savitt, J. M.; Pletnikova, O.; Troncoso, J. C.; Dawson, V. L.; Dawson, T. M.; Chung, K. K. Snitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(12), 4900-4905.
83. Gao, H. M.; Liu, B.; Zhang, W.; Hong, J. S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J., 2003, 17(13), 1954-1956.
84. Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G.; Costa, B. Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress. Phytother. Res., 2009, 23(12), 1678-1684.
85. Cassol-Jr, O. J.; Comim, C. M.; Silva, B. R.; Hermani, F. V.; Constantino, L. S.; Felisberto, F.; Petronilho, F.; Hallak, J. E.; De Martinis, B. S.; Zuardi, A. W.; Crippa, J. A.; Quevedo, J.; Dal-Pizzol, F. Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res., 2010, 1348, 128-138.
86. Martin, B. R.; Dewey, W. L.; Harris, L. S.; Beckner, J. S. 3Hdelta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. J. Pharmacol. Exp. Ther., 1976, 196(1), 128-144.
87. Bartova, A.; Birmingham, M. K., Effect of delta9-tetrahydrocannabinol on mitochondrial NADH-oxidase activity. J. Biol. Chem., 1976, 251(16), 5002-5006.
88. Sarafian, T. A.; Kouyoumjian, S.; Khoshaghideh, F.; Tashkin, D. P.; Roth, M. D. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am. J. Physiol. Lung Cell. Mol. Physiol., 2003, 284(2), L298-L306.
89. Costa, B.; Colleoni, M. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol. Eur. J. Pharmacol., 2000, 395(1), 1-7.
90. Velez-Pardo, C.; Jimenez-Del-Rio, M.; Lores-Arnaiz, S.; Bustamante, J. Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure. Neurochem. Res., 2010, 35(9), 1323-1332.
91. Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Hasko, G.; Pacher, P. Cannabidiol attenuates cisplatininduced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther., 2009, 328(3), 708-714.
92. Zheng, B.; Liao, Z.; Locascio, J. J.; Lesniak, K. A.; Roderick, S. S.; Watt, M. L.; Eklund, A. C.; Zhang-James, Y.; Kim, P. D.; Hauser, M. A.; Grunblatt, E.; Moran, L. B.; Mandel, S. A.; Riederer, P.; Miller, R. M.; Federoff, H. J.; Wullner, U.; Papapetropoulos, S.; Youdim, M. B.; Cantuti-Castelvetri, I.; Young, A. B.; Vance, J. M.; Davis, R. L.; Hedreen, J. C.; Adler, C. H.; Beach, T. G.; Graeber, M. B.; Middleton, F. A.; Rochet, J. C.; Scherzer, C. R. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med., 2010, 2(52), 52-73.
93. Scarpulla, R. C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev., 2008, 88(2), 611-638.
94. Wu, Z.; Puigserver, P.; Andersson, U.; Zhang, C.; Adelmant, G.; Mootha, V.; Troy, A.; Cinti, S.; Lowell, B.; Scarpulla, R. C.; Spiegelman, B. M. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 1999, 98(1), 115-124.
95. Safdar, A.; Little, J. P.; Stokl, A. J.; Hettinga, B. P.; Akhtar, M.; Tarnopolsky, M. A. Exercise increases mitochondrial PGC-1{alpha} content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis. J. Biol. Chem., (in press).
96. Tedesco, L.; Valerio, A.; Cervino, C.; Cardile, A.; Pagano, C.; Vettor, R.; Pasquali, R.; Carruba, M. O.; Marsicano, G.; Lutz, B.; Pagotto, U.; Nisoli, E. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes, 2008, 57(8), 2028-2036.
97. Mukhopadhyay, P.; Pan, H.; Rajesh, M.; Batkai, S.; Patel, V.; Harvey-White, J.; Mukhopadhyay, B.; Hasko, G.; Gao, B.; Mackie, K.; Pacher, P. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 2010, 160(3), 657-668.
98. Mukhopadhyay, P.; Rajesh, M.; Batkai, S.; Patel, V.; Kashiwaya, Y.; Liaudet, L.; Evgenov, O. V.; Mackie, K.; Hasko, G.; Pacher, P. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc. Res., 2010, 85(4), 773-784.
99. Ashton, J. C.; Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol., 2007, 5(2), 73-80.
100. Galve-Roperh, I.; Aguado, T.; Palazuelos, J.; Guzman, M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des., 2008, 14(23), 2279-2288.
101. Downer, E. J.; Gowran, A.; Campbell, V. A. A comparison of the apoptotic effect of Delta(9tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res., 2007, 1175, 39-47.
102. van der Stelt, M.; Di Marzo, V., Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med., 2005, 7(1-2), 37-50.
103. Angelucci, F.; Ricci, V.; Spalletta, G.; Pomponi, M.; Tonioni, F.; Caltagirone, C.; Bria, P. Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers. Eur. Neuropsychopharmacol., 2008, 18(12), 882-887.
104. Kim, S. R.; Chung, Y. C.; Chung, E. S.; Park, K. W.; Won, S. Y.; Bok, E.; Park, E. S.; Jin, B. K. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol. Neurobiol., 2007, 35(3), 245-254.